| 000 | 02810nam a22003377a 4500 | ||
|---|---|---|---|
| 001 | D0001C000078 | ||
| 003 | DOH | ||
| 005 | 20201126135901.0 | ||
| 008 | 201126b ||||| |||| 00| 0 eng d | ||
| 245 | 0 | 0 |
_aRisk factors and outcomes of hospitalized patients with severe COVID-19 and secondary bloodstream infections : _ba multicenter, case-control study / _cPinki J. Bhatt [and eleven others] |
| 500 | _aAccepted manuscript. | ||
| 520 | 3 | _aBACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic. Clinical characteristics regarding secondary infections in patients with COVID-19 have been reported but detailed microbiology, risk factors and outcomes of secondary bloodstream infections (sBSI) in patients with severe COVID-19 have not been well described. METHODS: We performed a multicenter, case-control study including all hospitalized patients diagnosed with severe COVID-19 and blood cultures drawn from March 1, 2020 to May 7, 2020 at three academic medical centers in New Jersey, USA. Data collection included demographics, clinical and microbiologic variables, and patient outcomes. Risk factors and outcomes were compared between cases (sBSI) and controls (no sBSI). RESULTS: A total of 375 hospitalized patients were included. There were 128 sBSIs during the hospitalization. For the first set of positive blood cultures, 117 (91.4%) were bacterial and 7 (5.5%) were fungal. Those with sBSI were more likely to have altered mental status, lower mean percent oxygen saturation on room air, have septic shock and be admitted to the intensive care unit compared to the controls. In-hospital mortality was higher in those with a sBSI versus controls (53.1% vs 32.8%, p=0.0001). CONCLUSIONS: We observed hospitalized adult patients with severe COVID-19 and sBSI had a more severe initial presentation, prolonged hospital course, and worse clinical outcomes. To maintain antimicrobial stewardship principles, further prospective studies are necessary to better characterize risk factors and prediction modeling to better understand when to suspect and empirically treat for sBSI in severe COVID-19. | |
| 580 | _aIn: Clinical Infectious Diseases, ciaa1748, https://doi.org/10.1093/cid/ciaa1748 | ||
| 650 | 2 | _aCoronavirus Infections | |
| 653 | _aBloodstream Infections | ||
| 653 | _aCOVID-19 | ||
| 700 | 1 | _aBhatt, Pinki J. | |
| 700 | 1 | _aShiau, Stephanie | |
| 700 | 1 | _aBrunetti, Luigi | |
| 700 | 1 | _aiXie, Yingda | |
| 700 | 1 | _aSolanki, Kinjal | |
| 700 | 1 | _aKhalid, Shaza | |
| 700 | 1 | _aMohayya, Sana | |
| 700 | 1 | _aAu, Pak Ho | |
| 700 | 1 | _aPham, Christopher | |
| 700 | 1 | _aUprety, Priyanka | |
| 700 | 1 | _aNahass, Ronald | |
| 700 | 1 | _aNarayanan, Navaneeth | |
| 856 | _uhttps://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1748/5995838 | ||
| 942 | _cCV | ||
| 999 |
_c1853 _d1853 |
||